A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement (clinicaltrials.gov) - Sep 3, 2026 - P2 | N=38 | Recruiting | Sponsor: Mehmet Akce | Trial completion date: Jul 2027 ➔ Jul 2028 | Trial primary completion date: Jul 2026 ➔ Jul 2027
Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Gallbladder Cancer • Oncology • Solid Tumor • FGFR2
|